Regen BioPharma Inc (RGBP)

[SidVicious]

All Lilly did was allow Regen access to their molecule library to test molecules against the NR2F6 receptor. Speculation was that Lilly, assuming Regen was successful, would end up licensing the patent. A ex Lilly exec even briefly joined Regen's board.

https://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-former-eli-lilly-executive-and-current-cvs-board-member-will-lead-newly-formed-business-advisory-board-bab-654072053.html

Guess how that all ended? With nada, zilch, zero.

Another Koos failure in a long line of failures.

The on ph deal will result in failure as well. MARK MY WORDS.